Form 4 for SPRY ARS Pharmaceuticals, Inc.
Accepted 2022-11-10 00:00:00 ET · period of report 2022-11-08 · accession 0001209191-22-056445 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2022-11-10 | 2022-11-08 | SPRY | Shah Pratik | Dir, 10% | A - Grant | — | +10.16M | 10.16M | New | — |
| D | 2022-11-10 | 2022-11-08 | SPRY | Shah Pratik | Dir, 10% | A - Grant | — | +354.6K | 354.6K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-08 | A | A | 10,156,204 | — | 10,156,204 | I By The Pratik Shah Living Trust dated June 15, 2011 | — | — | (F1) Received in exchange for 8,593,116 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc. (F2) These shares are held in a trust for the benefit of the Reporting Person. The Reporting Person is trustee of the trust. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2022-11-08 | A | A | 354,570 | — | 354,570 | D | $1.44 · — to 2031-11-30 | 354,570 Common Stock | (F4) Received in exchange for a stock option to acquire 300,000 shares of common stock of ARS with the exercise price of $1.70 per share pursuant to the Merger Agreement. (F5) Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. (F3) The shares subject to the option vest in a series of thirty-six (36) equal monthly installments measured from the vesting commencement date. |